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Background: Suicide gene therapy for malignant gliomas has shown encouraging 
results in the latest clinical trials. However, prodrug application was most often 
restricted to short-term treatment (14 days), especially when replication-defective 
vectors were used. We previously showed that a substantial fraction of Herpes simplex 
virus thymidine kinase (HSV-TK) transduced tumor cells survive ganciclovir (GCV) 
treatment in an orthotopic glioblastoma (GBM) xenograft model. Here we analyzed 
whether these TK+ tumor cells are still sensitive to prodrug treatment and whether 
prolonged prodrug treatment can enhance treatment efficacy.  
Methods: TK-GFP+ glioma cells were sorted from xenograft tumors recurring after 
suicide gene therapy, and their sensitivity to GCV was tested in vitro. GBM xenografts 
were treated with HSV-TK/GCV, HSV-TK/valganciclovir (valGCV) or HSV-
TK/valGCV + erlotinib. Tumor growth was analyzed by MRI, and survival as well as 
morphological and  molecular changes were assessed. 
Results: TK-GFP+ tumor cells from recurrent xenograft tumors retained sensitivity to 
GCV in vitro. Importantly, a prolonged period (3 months) of prodrug administration 
with valganciclovir (valGCV) resulted in a significant survival advantage compared to 
short-term (3 weeks) application of GCV. Recurrent tumors from the treatment groups 
were more invasive and less angiogenic compared to primary tumors and showed 
significant upregulation of epidermal growth factor receptor (EGFR) expression. 
However, double treatment with the EGFR inhibitor erlotinib did not increase 
therapeutic efficacy.  
Conclusions: Long-term treatment with valGCV should be considered as a 
replacement for short-term treatment with GCV in clinical trials of HSV-TK mediated 
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Key Points: 
 Prodrug administration scheme is a crucial factor in suicide gene therapy  




Importance of the study 
Clinical trials for suicide gene therapy of glioblastoma with the HSV-TK/Ganciclovir 
(GCV) system used short-term prodrug treatment (14 days) as a standard regimen for 
suicide induction. In an orthotopic PDX model for glioblastoma we demonstrate that a 
substantial fraction of tumor cells expressing the suicide gene HSV-TK survive short-
term treatment with the prodrug Ganciclovir. We verify that these tumor cells are not 
resistant to treatment, but retain sensitivity to GCV in vitro. We show that treatment 
with valganciclovir, an alternative prodrug allowing oral long-term administration 
significantly prolongs survival in a clinically relevant orthotopic PDX model. Thus, 
future clinical trials should consider long-term prodrug treatment to enhance the 




Glioblastoma (GBM) is the most aggressive primary brain tumor in humans. Standard 
therapy that involves maximal possible surgical resection followed by concomitant 
temozolomide chemotherapy and radiotherapy results in a median survival of 14.6 
months 1. Intrinsic heterogeneity 2 and local seclusion provided by the blood-brain-
barrier (BBB), combined with the infiltrative nature make it difficult to develop 
targeted therapeutics for GBM. 
Fairly efficient access of various prodrugs through BBB after systemic delivery has 
turned suicide gene therapy into a promising option for GBM treatment. Early clinical 
trials using replication-defective retroviral vectors encoding the suicide gene Herpes 
simplex virus thymidine kinase (HSV-TK) to transduce GBM cells followed by 
ganciclovir (GCV) application were disappointing, most likely due to low transduction 
efficiency 3,4,5,6. One major drawback of retroviral vectors is the incapability of 
transducing quiescent cells. In contrast lentiviral vectors efficiently transduce  
quiescent cells which is mediated by the karyophilic nature of the lentiviral pre-
integration complex 7. Indeed, we observed significantly higher in vitro transduction 
rates of biopsy-derived and cancer-stem-like glioma cells compared to retroviral 
vectors 8. We also showed that HSV-TK transduced normal brain cells are not killed by 
GCV prodrug treatment 9 and nonetheless can contribute to eliminating tumor cells 
through the bystander effect 10. By using lentiviral suicide gene therapy in a biopsy-
derived GBM xenograft model, we demonstrated complete remission of GBM on MRI 
with a significant survival benefit 8. However, tumor recurrence was observed in all 
animals after termination of GCV administration. Importantly, we observed that a 
fraction of HSV-TK transduced tumor cells survived even after 4 weeks of GCV 
application 8. At this point it was not known if HSV-TK in these tumor cells retained 
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functionality. In the present study, we show that the HSV-TK+ recurrent tumor cells 
harbor functional HSV-TK, which indicates that the duration of GCV application likely 
has not been long enough to efficiently target the slowly dividing or relatively-quiescent 
glioma cells. By using valganciclovir (valGCV) as a prodrug we confirmed our 
hypothesis showing significantly increased survival after long-term prodrug 
administration.  
 
Materials and methods 
Ethics statement 
The Norwegian Data Inspectorate and the Regional Committee for Ethics in Research 
have approved this project (REK 013.09). The study was performed in accordance with 
the Helsinki Declaration. 
 
Cells and spheroids 
Biopsy material was obtained from resection surgery of a GBM patient (patient 3; P3) 
11 in Haukeland University Hospital according to a similar protocol mentioned 
previously 12,13. Resultant GBM spheroids were passaged in vivo by serial implantation 
in Rowett nude rats (RNU). Details of culture condition and generation of spheroids 




Healthy RNU rats were procured and provided with standard pellet diet and water ad 
libitum. Animals were treated in accordance with the Norwegian Animal Act. The local 




Lentiviral vector construction, production and injection 
Lentiviral vectors were constructed, prepared and injected intratumorally following  
protocols reported previously 14. 
 
MRI 
Details of brain MRI sequences have been reported previously 14. 
 
Treatment 
GCV (Cymeven; F. Hoffmann-La Roche) was given 50 mg/kg/day i.p. for 3 weeks and 
valGCV (Valcyte; F. Hoffmann-La Roche)  was given 80 mg/kg/day P.O. for either 3 
months or in cycles starting from 5 days after vector infusion. Erlotinib (Tarceva; F. 
Hoffmann-La Roche) was dissolved in acidified water (pH 4.8), mixed at an 1:1 ratio 
with 0.2%   carboxymethylcellulose and was given P.O. 20 mg/kg/day for 5 days a 
week. This dosage resulted in side effects manifested by rash and weight reduction and 
led us to reduce the dose after 1 week to 5 mg/kg/day for 5 days a week which did not 
further result in any detectable side effects.  
 
Immunohistochemistry and Immunofluorescence 
Immunohistochemistry of paraffin sections was performed as described previously 8. 
Immunofluorescence was performed as described in the supplementary methods. 
Dilution of primary antibodies is described in the supplementary methods. Images were 
acquired with Nikon E600 light microscope (Nikon Corporation) , NanoZoomer XR 
scanner (Hamamatsu Photonics) and Nikon widefield fluorescent microscope TE2000 




Digital analysis of images  
Described in supplementary methods. 
 
Statistics 
Survival analysis was performed by Kaplan-Meier estimator with log rank test using 
graphpad prism software (GraphPad Software Inc). Other statistical analyses were 
performed by STATA software (StataCorp) or R (RStudio version 1.1.383) by t-test or 
ANOVA (P<0.05 was considered significant). Significant ANOVA results were 
followed by post-hoc pairwise comparisons with either Tukey’s or Dunnett’s 
adjustment for multiple comparisons. In the case of heteroscedasticity, dependent 
variables were log- or square root-transformed, depending on suitability.  
 
Gene Expression Data Analysis 
Whole-genome RNA sequencing was carried out at Macrogen Inc. (South Korea) on 





TK+ glioma cells that survive short-term prodrug administration retain sensitivity 
towards GCV in vitro  
Previously we have shown that a fraction of tumor cells expressing HSV-TK survive 
GCV prodrug treatment and are present in recurrent tumors 8. These cells either may 
have become resistant to prodrug treatment or may be more quiescent than other tumor 
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cells in vivo. Here we investigated whether these remaining TK-transduced cells retain 
or lose sensitivity towards GCV. Intratumoral injection of lentiviral vectors encoding 
TK.007 14, a recombinant HSV-TK with superior functionality 15,16, followed by GCV 
administration for 3 weeks resulted in tumor remission on MRI (Suppl. Fig. 1A). 
Recurrent tumors, which developed 7-8 weeks later, were dissociated and maintained 
in short-term culture. TK+ cells were sorted from the cultures based on eGFP expression 
and immunostaining for human nestin confirmed that these cells were tumor cells of 
human origin (Fig. 1A). Treatment of the sorted TK+ glioma cells with GCV in vitro 
showed that the cells retained sensitivity towards GCV (Fig. 1B). Upon further 
characterization of the cultured TK+- and TK− -glioma cells from the recurrent tumors, 
we observed no difference in terms of expression of glioma stem cell markers such as 
CD133, SOX2 and Nestin (Suppl. Fig. 1B). Similarly, there was no indication of a 
switch towards a mesenchymal or proneural subtype by using YKL40 and olig2 
markers respectively (Suppl. Fig. 1B). In conclusion, TK+ glioma cells do not become 
resistant to prodrug treatment over time. 
 
Long-term valGCV administration improves the therapeutic effect of suicide gene 
therapy for experimental GBM  
The sustained GCV sensitivity of the TK+ cells indicated that the current prodrug 
scheme of 2-3 weeks of GCV treatment, which was also used in clinical trials for 
suicide gene therapy 6,17, is too short to eliminate all transduced tumor cells. To assess 
the effect of prolonged prodrug administration we introduced the drug valGCV, which 
is metabolized into GCV in the intestinal wall and liver 18. valGCV is given orally and 
thus is suitable for long-term administration 19. In contrast, GCV is given i.v. to patients 
by using catheters, which can cause infections upon long-term use 20. We compared the 
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therapeutic benefit of long-term valGCV administration (3 months) with short-term (3 
weeks) GCV treatment in the same orthotopic xenograft model. During treatment, the 
majority of animals from both treatment groups showed rapid reduction in tumor 
growth followed by tumor remission on MRI within 3-4 weeks (Fig. 2A). Kaplan-Meier 
survival analyses revealed that the TK/valGCV treatment group had a significant 
survival benefit compared to the TK/GCV group (Fig. 2B). Interestingly one animal 
from the valGCV treatment group was apparently cured and sacrificed healthy after 
more than 6 months of tumor remission (Suppl. Fig. 2A). All other animals in the 
valGCV treatment group developed recurrences distant from the primary site and often 
close to or in the brainstem (Suppl. Fig. 2B), which might explain why the  difference 
in survival between the two treatment groups was not more extensive. 
 
Continuous valGCV application eliminates the majority of TK+ tumor cells  
The majority of animals demonstrated tumor recurrence at various time periods after 
initial remission on MRI. While in the GCV treatment group 4 out of 4 animals showed 
local recurrences, all animals in the valGCV group showed recurrences that were 
distant from the primary site indicating that highly invasive cells escaped the treatment 
(Fig. 3A). Next, we analyzed whether TK-transduced cells had survived long-term 
treatment with valGCV. While TK-transduced cells were abundant in the recurrences 
of GCV treated animals, the distant recurrences of valGCV-treated animals were 
negative for the TK-transgene. However, scattered TK-positive cells were detected at 
the primary site of valGCV treated animals (Fig. 3B). When quantifying the number of 
transduced tumor cells on double immunofluorescence stained sections with antibodies 
against human nestin and GFP (Fig. 3C), we identified a significantly lower number of 
transduced residual glioma cells in the valGCV group compared to the GCV group  
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(Fig. 3D). Further, we observed that the residual TK+ cells in the short-term GCV group 
are significantly less proliferative than the TK− cells (Fig. 3E). We conclude that 
prolonged valGCV application facilitates the elimination of slow-proliferating glioma 
cells that are spared by current short-term treatment regimen. 
 
Recurrent tumors are more invasive and less angiogenic compared to the primary 
tumors  
Histological analyses revealed that the recurrent tumors from both treatment groups 
were more invasive and showed reduced vascularization/angiogenesis compared to the 
primary tumors from the control groups (Fig. 4A-F). Nestin immunohistochemistry 
revealed that GCV-treated tumors exhibited a diffuse growth pattern with extensive 
infiltration into the neighboring anatomical structures such as corpus callosum and even 
the contralateral hemisphere (Fig. 4A). Quantification of number of invasive cells 
outside the solid tumor mass confirmed that GCV-treated tumors were significantly 
more invasive compared to control tumors which both were found close to the primary 
injection site (Fig. 4B). All  recurrent tumors of the valGCV group were found distant 
from the primary site which confirms that these tumors were initiated by highly 
invasive cells that escaped the treatment. When analyzing angiogenic/hypoxic features, 
primary tumors showed highly abundant necrotic areas and characteristic 
microvascular proliferations, which both were absent in local and distant recurrences 
(Fig. 4C). Immunostaining for vWF confirmed smaller vessels in the distant and local 
recurrent tumors compared to the primary tumors (Fig. 4D). Quantification of the vessel 
area fraction showed that the differences between primary and overall recurrent tumors 
(Fig. 4E), but not between the local and distant recurrences (Fig. 4F) were statistically 
significant. Apparently, there was an emergence of invasive glioma cells that escaped 
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prodrug treatment and established a secondary tumor mass mostly in brain regions 
distant from the primary site. Thus, we aimed at testing whether administration of 
valGCV in cycles (analogous to chemotherapy) might lower the threshold of surviving 
tumor cells for inducing an invasive escape program. We compared continuous valGCV 
treatment to cyclic valGCV using the experimental setup as described for Fig. 2. 
However the cyclic administration scheme neither showed any improved therapeutic 
effect nor resulted in reduced infiltrative nature of the recurrent tumors (Suppl. Fig. 3A 
and 3B). 
 
Distant tumor recurrences show upregulation of EGFR and downregulation of 
pSTAT3 
Due to the different growth pattern of distantly recurrent tumors in the valGCV group, 
we analyzed important molecular pathways involved in glioblastoma development by 
immunohistochemistry in order to identify proteins that might drive recurrent and 
invasive tumor growth. We performed immunostainings for (1) the tyrosine kinase 
receptors EGFR, PDGFR-A and c-MET, which often are amplified or co-amplified in 
GBM; (2) pMAPK and pSTAT3, which are activated downstream of tyrosine kinase 
signaling; (3) olig2, a protein abundantly expressed in glial tumors (Fig. 5 A,C,E and 
Suppl. Fig. 4A). c-MET, olig2 and pMAPK were equally expressed in all groups 
without obvious differences. However, there was a striking difference in EGFR 
expression: while the primary tumors were negative for EGFR, we observed EGFR 
expression in the recurrent tumors (Fig. 5A). Quantification of EGFR 
immunohistochemistry revealed that recurrent tumors expressed significantly higher 
EGFR in general and interestingly, distant recurrences further showed a significantly 
higher EGFR expression level compared to the local recurrences (Fig. 5B). To check if 
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the EGFR upregulation involved amplification events, we performed FISH for 
EGFR/CHR7 which only showed CHR7 gain, but no amplification in both treatment 
and control groups (Suppl. Fig. 4B). In addition to EGFR upregulation, we found 
differential expression of PDGFR-A, which exhibited uniform and abundant expression 
in the recurrent tumor tissue, while it was very heterogeneously expressed in primary 
tumors with strong expression in the vessel wall, but weaker in the tumor tissue (Fig. 
5C). Quantification revealed that there was a significant difference in PDGFR-A 
expression between primary versus recurrent tumors, but not between local versus 
distant recurrences (Fig. 5D). pSTAT3, in contrast, was significantly downregulated in 
recurrent tumors compared with primary tumors (Fig. 5E,F). However, these 
differential expression patterns did not affect proliferative activity as shown by Ki-67 
staining (Fig. 5G,H).  
 
Recurrent tumors are resistant to Erlotinib treatment  
Based on our observation that EGFR is upregulated in the recurrent tumors after gene 
therapy, we hypothesized that a combinatorial treatment regimen involving gene 
therapy plus anti-EGFR treatment would further improve the therapeutic benefit. To 
test this, we compared a combination therapy consisting of gene therapy plus erlotinib, 
a small-molecule EGFR inhibitor, with gene therapy alone. Resembling our previous 
animal experiments, tumor remission (on MRI) was observed within a 3-4 week time 
period in both treatment groups (data not shown) followed by tumor recurrences at later 
time points. Kaplan-Meier survival analysis showed that there was no survival 
difference between gene therapy-only and combination therapy (Fig. 6A). To analyze 
the effect of Erlotinib on EGFR phosphorylation we immunostained brain sections of 
the different groups with anti-pEGFR (1068) antibodies (Fig. 6B). We observed a trend 
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of reduced EGFR phosphorylation in the double treatment group compared to the gene 
therapy-only group (Fig. 6C). We also immunostained brain sections with an anti-
EGFR antibody, which showed significant upregulation of  EGFR expression in the 
combination treatment group compared to the gene therapy-only group (Fig. 6D, 6E). 
Thus, compensatory upregulation of EGFR in the tumor cells might impede the effect 
of anti-EGFR treatment. 
 
 
Transcriptome profiling of recurrent tumors after TK+valGCV treatment 
To identify global transcriptional changes associated with tumor recurrence after 
TK+valGCV treatment, we performed RNA sequencing. Interspecies variability of the 
sequences showed equal contamination by host tissue among all samples except one 
which was excluded (Suppl. Fig. 5A). Gene expression differential analysis revealed 
262 genes upregulated and 139 genes downregulated (padj<0.05) when comparing the 
gene expression profile between the TK+valGCV and valGCV-only group (Suppl. Fig. 
5B; Suppl. Fig. 6A,B; Suppl. table 1). Among the upregulated genes we detected EGFR 
(Suppl. Fig. 6B), confirming the previous results from immunohistochemistry in Figure 
5. Biological processes/pathways associated with the transcriptional changes were 
identified by gene set enrichment analyses (GSEA). “Cellular response to hypoxia” and 
“vasculogenesis” were major processes associated with control tumors (Suppl. Fig. 6C, 
Suppl. tables 2 and 3) confirming our previous results showing increased angiogenesis 
in this group (Figure 4). Recurrent tumors from the TK+valGCV group exhibited 
upregulation of “Wnt signaling pathway” and “Cell adhesion molecules (CAMs)” 
among others (Suppl. Fig. 6D, Suppl. tables 2 and 3) indicating several invasive escape 






In suicide gene therapy of brain tumors, 1-2 weeks of prodrug treatment is a standard 
regimen that by default, has been used in pre-clinical studies and clinical trials with 
replication-deficient vectors so far 3,6,17,21-24. A similar prodrug administration scheme 
of maximum 2 weeks also dominates the ongoing clinical trials with replication-
defective vectors (ClinicalTrials.gov Identifier: NCT03596086, NCT03603405, 
NCT00634231). This regimen had been tested extensively in animal models and had 
shown success there. However, tumors in animal models proliferate at a higher rate 
compared to the human situation, and in particular animal models based on serum-
cultured monolayer cell lines exhibit a highly proliferative and non-invasive behavior 
25. The killing of tumor cells by GCV triphosphate (GCV-TP) is only mediated in 
proliferative cells as GCV-TP is incorporated as a nucleotide-analogon into the host 
DNA of dividing cells and terminates DNA synthesis. Thus, tumor cells are killed much 
faster in highly proliferating tumors compared to slow proliferating ones when using 
HSV-TK/GCV suicide gene therapy. For our study, we employed one of the most 
clinically relevant animal models for GBM 12 that closely recapitulates patient histology 
upon orthotopic implantation, retains major genetic changes of patient GBM and shows 
a similar proliferation rate 25. Importantly, this PDX model shows profound 
heterogeneity at the single cell level and contains tumor cells from proneural, neural, 
classical and mesenchymal subtypes (unpublished data). Using this model system, we 
previously showed that lentiviral-vector mediated HSV-TK/GCV gene therapy is a 
highly promising therapeutic option for GBM 8. However, a substantial fraction of TK+ 
tumor cells were found to escape the standard GCV treatment. At that time, the 
N-O-D-18-00796R1 
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mechanism of survival of residual TK-transduced tumor cells remained open. Genomic 
deletion or transgene silencing were described as one potential mechanism of TK 
resistance after retroviral-vector mediated delivery26, but expression of the transgene is 
still detectable in transduced cells that survived treatment in our model. Aberrant 
transcription 27 or splicing 28 can result in expression of non-functional TK. However, 
TK.007 involves codon corrections and optimizations, which remove the cryptic sites 
in question. Moreover, the extensive codon-optimization of TK.007 has removed many 
of the hot-spots for mutations described for wild-type TK 29, although the generation of 
potential new sites prone to to mutation could not be excluded.  
However, we hypothesized that a fraction of the TK-expressing cells might become 
resistant through quiescence. In this work we showed that resistant TK+ glioma cells 
indeed were slowly proliferating in vivo and retained sensitivity to ganciclovir in vitro. 
This data supported our assumption that the standard treatment of 2-3 weeks might be 
not long enough to kill all (or at least the vast majority of) transduced cells. In turn, it 
was suggestive to propose that a prolonged scheme of prodrug administration should 
result in better therapeutic outcome. However, systemic GCV treatment is associated 
with various drawbacks including cathether infections and thus is not a suitable option 
for long-term administration 18. Instead, we decided to use valGCV as a prodrug, which 
is established as a preemptive treatment regimen in CMV disease and has been 
documented to be safe and well-tolerated by GBM patients after administration for 
more than 6 months 30. valGCV is tailored as an oral formulation that readily gets 
metabolized to the active form (ganciclovir) in the intestinal wall and the liver 31. Due 
to its similar efficacy compared to intravenous GCV, significantly higher 
bioavailability than oral GCV and safer mode of administration than intravenous GCV, 
valGCV has become a standard drug in clinical practice for CMV infection 18 . 
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In line with our hypothesis, we observed a significant survival benefit of the prolonged 
valGCV treatment regimen and significant reduction of TK+ cells compared to GCV 
short-term treatment. However, except for one rat in the valGCV group, all other rats 
demonstrated tumor recurrence at various time points after initial tumor remission. 
Interestingly, the recurrence patterns between GCV and valGCV groups were spatially 
different. The distant recurrences of the valGCV-treated animals lacked tumor cells 
with TK.007-eGFP expression suggesting that highly invasive tumor cells that had not 
been transduced with TK escaped the treatment. Histological, transcriptomic and 
immunohistochemical analyses confirmed that recurrent tumors were more invasive 
and less angiogenic compared to the primary tumors while the primary tumors involved 
abundant necrotic areas and microvascular proliferation. Enhanced invasion of 
recurrent GBMs was also observed in other therapeutic settings such as bevacizumab 
treatment most likely induced by hypoxia 32-34. In our setting, intermittent hypoxia 
could also play a role since lentiviral vectors can transduce endothelial cells 35, and 
killing these cells through HSV-TK/GCV could lead to less vascularization and 
hypoxia. Thus, similar mechanisms could be involved in inducing tumor invasion in 
different therapeutic settings.  
Molecular characterization of the recurrent tumors by RNA sequencing and 
immunohistochemical analyses revealed upregulation of EGFR. The level of 
expression was also significantly higher in distant compared with local recurrences. 
EGFR was previously associated with tumor invasion in many different cancer types 
36-39, and we previously showed that EGFR mediates invasion of tumor cells 
independent of angiogenesis 13,40. Keunen et al. showed upregulation of EGF in 
bevacizumab treated GBM xenografts indicating that hypoxia and a lack of blood 
supply could be a potential mechanism for EGFR upregulation/activation 33. Thus, 
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EGFR appeared to be an attractive target for a combinatorial treatment setting with 
suicide gene therapy to prevent tumor recurrence. Erlotinib is a prominent EGFR 
inhibitor that can cross the BBB 41-43 and downregulates EGFR activation 
(phosphorylation). There was a trend of reduced activation of EGFR upon erlotinib 
administration, but it was neither significant nor was it translated into therapeutic 
benefit (and /or reduced invasion of tumor cells). Inhibition of EGFR phosphorylation 
was reported to trigger various adaptive responses and thereby can resist therapy 44-46. 
In line, single inhibition of EGFR by erlotinib was shown to be ineffective in a glioma 
PDX model unless combined with other inhibitors to target the corrsponding associated 
proteins that drive reactive compensatory mechanisms 45. It is noteworthy in this 
context that gene enrichment analysis of RNA sequencing data revealed upregulation 
of additional genes/pathways in the TK+valGCV treated tumors including WNT 
signaling, which is known to be an important player of glioma invasion 47. 
In conclusion, we show that the prodrug administration scheme is a key factor for 
suicide gene therapy of GBM. We report that long-term treatment with the prodrug 
valGCV improves HSV-TK suicide gene therapy for GBM by killing the tumor cells 
that still retain sensitivity towards the prodrug but are not eliminated by the standard 
short-term GCV treatment. Based on our results, prolonged and continuous 
administration of prodrug should be considered for suicide gene therapy studies and/or 
clinical trials for brain tumors in the future.  
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Figure 1: TK+ glioma cells that survive short-term prodrug administration retain 
sensitivity towards GCV in vitro. (A) Immunofluorescence staining with antibodies 
against human nestin (red) and GFP (green). Scale bar: 50 µm (B) Cell viability assay 
showing % of surviving cells after increasing concentrations of GCV; i.v.TK+: The 
TK— cells present in the recurrent tumor were transduced with the same lentiviral vector 
in vitro. 
 
Figure 2: Long-term administration of valGCV is more efficient compared to 
short-term GCV treatment in vivo. (A) Representative MRI (T2 RARE) images are 
shown. The solid tumor regions are marked with dashed lines. (B) Kaplan-Meier 
survival analysis: 3-month valGCV treatment has a significant survival benefit 
compared with the 3-week GCV treatment (p=0.008).  
 
Figure 3: Continuous valGCV application eliminates the majority of TK+ tumor 
cells. (A) H&E stainings of recurrences (left panel: recurrence at the primary site in 
GCV treatment group, right panel: recurrence distant from the primary site in valGCV 
treatment group) (B) Immunohistochemistry with antibodies for HSV-TK show 
transduced cells in the recurrent tumor mass. (C) Double immunofluorescent staining 
using antibodies against human nestin (green) and GFP (red) for the TK.007-eGFP 
fusion protein. Representative images show TK.007-eGFP+ tumor cells that survived 
prodrug treatment. Scale bar: 50 μm. (D) Quantification of the remaining tumor cells 
expressing TK.007-eGFP: percentage of residual TK+  tumor cells in 3-month long 
valGCV treated group is lower compared with the short-term GCV-treatment group 
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(p=0.042). (E) Proliferative capacity of the remaining TK+ cells is significantly lower 
compared with TK— cells (p= 0.041) in the TK+GCV group.  
 
Figure 4: Recurrent tumors after gene therapy are more invasive and less 
angiogenic compared with primary tumors. (A) Immunostaining with human nestin 
antibody showing extensive infiltration of glioma cells into corpus callosum in local 
and distant recurrent tumors, but not in the primary tumor. (B) Quantification of 
invasive tumor cells outside the solid tumor mass in control tumors and local 
recurrences (TK+GCV) (C) H&E stainings of primary and recurrent tumors showing 
necroses and microvascular proliferation only in the necrotic tumors. (D) vWF 
immunostaining reveals reduced angiogenesis in recurrent tumors compared to primary 
tumors. Scale bar 50 µm (E, F) Quantification of vessel area fraction among the groups. 
Overall recurrent tumors have significantly reduced vessel area compared to primary 
tumors (p=0.001).  
 
Figure 5: EGFR is upregulated in recurrent tumors after suicide gene therapy. 
Immunohistochemical stainings with antibodies against EGFR (A), PDGFR-A (C), 
pSTAT3 (E) and Ki67 (G). Quantification showing percentage of EGFR+ (B), PDGFR-
A+ (D) area fraction and pSTAT3+ cells (F). Scale bar : 50 µm (H) Quantification of 
Ki-67+ cells; mean±SD 
 
Figure 6: Combination of suicide gene therapy with Erlotinib does not improve 
therapeutic efficacy. (A) Kaplan-Meier survival analysis does not show a significant 
difference between double treatment and single treatment arms. (B) 
Immunohistochemical stainings with antibodies against pEGFR 1068. Scale bar : 50 
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µm (C) Quantification showing percentage of pEGFR 1068+ area fraction (D,E) 
Immunohistochemical stainings with antibodies against EGFR and quantification of 
EGFR+ area fraction. 
 
 
 
 
 
 
 
 
 
 
